<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>drug interactions on Russell E. Lewis</title>
    <link>https://russlewisid.com/categories/drug-interactions/</link>
    <description>Recent content in drug interactions on Russell E. Lewis</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Mon, 28 Feb 2022 00:00:00 +0000</lastBuildDate><atom:link href="https://russlewisid.com/categories/drug-interactions/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Managing drug interactions with targeted chemotherapy</title>
      <link>https://russlewisid.com/blog/social/</link>
      <pubDate>Mon, 28 Feb 2022 00:00:00 +0000</pubDate>
      
      <guid>https://russlewisid.com/blog/social/</guid>
      <description>Brüggemann RJ, Verheggen R, Boerrigter E,Stanzani M, Verweij P, Blijlevens NMA, Lewis, RE. Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematol 2022;9:e58–e72. Available at: http://dx.doi.org/10.1016/S2352-3026(21)00232-5.
Abstract Over the past 10 years, the number of targeted therapies for haematological malignancies has substantially increased, and many new drugs have entered the market. Many of these therapies have shown improved disease-free survival and reduced toxicity compared with existing treatments, especially in older patients.</description>
    </item>
    
  </channel>
</rss>
